ISRCTN48215558 https://doi.org/10.1186/ISRCTN48215558

International Collaborative Ovarian Neoplasm studies (2): a trial of CAP versus carboplatin in advanced ovarian cancer

Submission date 28/02/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 28/02/2001	**Overall study status** Completed	
Last Edited 09/07/2014	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Claire Amos

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ICON2

Study information

Scientific Title

Study objectives
To compare cyclophosphamide, doxorubicin and cisplatin (CAP) with single-agent carboplatin in patients with advanced ovarian cancer.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Ovarian cancer

Interventions
1. Cyclophosphamide, doxorubicin and cisplatin (CAP)
2. Single-agent carboplatin

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Cyclophosphamide, doxorubicin, cisplatin, carboplatin

Primary outcome measure
1. Survival time
2. Progression-free survival

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1991

Completion date
31/12/1996

Eligibility

Key inclusion criteria
1. Chemotherapy indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy

Participant type(s)
Patient

Age group
Not Specified

Sex
Female

Target number of participants
2000 in 9 countries

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
01/01/1991

Date of final enrolment
31/12/1996

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/11/1998		Yes	No